Lupin informs about press release

08 Jan 2019 Evaluate

Lupin has informed about submission of a Press Release as regards receipt of European Commission approval for NaMuscla® (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. Non-dystrophic myotonic disorders are a group of rare inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. It is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company's filings submitted to BSE.


Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×